MannKind (MNKD) Scheduled to Post Quarterly Earnings on Thursday

MannKind (NASDAQ:MNKD) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect MannKind to post earnings of $0.04 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The business had revenue of $72.39 million during the quarter, compared to the consensus estimate of $64.81 million. MannKind had a negative return on equity of 11.97% and a net margin of 4.73%. The company’s quarterly revenue was up 48.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.02) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 2.4 %

NASDAQ:MNKD opened at $7.26 on Wednesday. MannKind has a twelve month low of $3.17 and a twelve month high of $7.32. The company has a market cap of $2.00 billion, a PE ratio of 181.50 and a beta of 1.30. The company’s 50 day moving average is $6.47 and its two-hundred day moving average is $5.51.

Insider Buying and Selling at MannKind

In other news, EVP Steven B. Binder sold 5,055 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $5.94, for a total transaction of $30,026.70. Following the transaction, the executive vice president now owns 1,075,026 shares in the company, valued at $6,385,654.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Stuart A. Tross sold 25,000 shares of MannKind stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.26, for a total value of $156,500.00. Following the sale, the insider now directly owns 1,022,191 shares of the company’s stock, valued at $6,398,915.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Steven B. Binder sold 5,055 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $5.94, for a total value of $30,026.70. Following the sale, the executive vice president now owns 1,075,026 shares of the company’s stock, valued at $6,385,654.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 195,161 shares of company stock valued at $1,229,095. Company insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MNKD. Oppenheimer upped their target price on MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. Leerink Partners assumed coverage on shares of MannKind in a report on Monday, September 9th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Leerink Partnrs raised shares of MannKind to a “strong-buy” rating in a report on Monday, September 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.67.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.